click below
click below
Normal Size Small Size show me how
biofactorsofdrugs
Biological Factors Affecting the Action of Drugs
| Question | Answer |
|---|---|
| bioavailability | percentage of the drug dosages that is absorbed |
| drug absorption | entrance of a drug into the bloodstream from its site of admin |
| drug addiction | condition of drug abuse and drug dependence that is characterized by compulsive drug behavior |
| drug dependence | condition of reliance on the use of a particular drug, characterized as physical and/or psychological dependence |
| drug distribution | passage of a drug from the blood to the tissues and organs of the body |
| drug microsomal metabolizing system (DMMS) | group of enzymes located primarily in the liver that function to metabolize (biotransformation) drugs |
| drug tolerance | decreased drug effect occurring after repeated drug admin |
| enzyme induction | increase in the amount of drug-metabolizing enzymes after repeated admin of certain drugs |
| enzyme inhibition | inhibition of drug-metabolizing enzymes by certain drugs |
| first-pass metabolism | drug metabolism that occurs following oral absorption from the GI tract |
| half-life | time req'd for the body to rid itself of half of the drug dosage that was absorbed (percent bioavailability) |
| individual variation | difference in the effects of drugs and drug dosages from one person to another |
| intramuscular injection | route of drug admin; drug is injected into gluteal or deltoid muscles |
| intravenous injection | route of drug admin; drug is injected directly into a vein |
| loading dose | initial drug dose admin to rapidly achieve therapeutic drug concentrations |
| maintenance dose | dose admin to maintain drug blood levels in the therapeutic range |
| oral admin | route of drug admin by way of the mouth through swallowing |
| parenteral admin | route of drug admin that does not involve the GI tract |
| receptors | site of action |
| FDA pregnancy categories | guidelines that classify drugs based on fetal risk |
| pregnancy category A | have not yet demonstrated risk to fetus |
| pregnancy category B | have not been performed in pregnant women; animal studies have not demonstrated fetal risk |
| pregnancy category C | have not been performed in pregnant women or in animals, or animal studies have revealed some teratogenic potential but the risk of the fetus is unknown |
| pregnancy category D | have revealed adverse risk to fetus; benefit-to-risk ratio of the drug must be established before use during pregnancy |
| pregnancy category X | have revealed teratogenic effects in women and/or animals; fetal risk clearly outweigh benefit; contraindicated in pregnancy |
| pregnancy category NR | has not yet been rated by the FDA |
| neonate | age 0 to 1 month |